Institutul Oncologic Prof. Dr. Ion Chiricuta

Cluj-Napoca 400015

5 studies enrolling now · 14 studies all time

What they study most

Acute Myeloid Leukemia, Adenocarcinoma, Advanced Non-small Cell Lung Cancer, HER2 Mutation, B Cell Precursor Acute Lymphoblastic Leukemia, Carcinoma, Non-Small-Cell Lung, Chemotherapy-Induced Nausea and Vomiting, Chronic Myelomonocytic Leukemia, Glioma, Metastatic Non-small Cell Lung Cancer, Myelodysplastic Syndromes, Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL), Non-small Cell Lung Cancer

Studies at this site

• A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) — Recruiting now
• A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors — Recruiting now
• Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment — Recruiting now
• Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment — Recruiting now
• A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) — Enrolling by invitation
• A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy — Running, not enrolling
• Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia — Running, not enrolling
• A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL — Running, not enrolling
• A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma — Completed
• KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment — Status unconfirmed
• An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting — Completed
• Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer — Completed
• BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation — Completed
• A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors — Completed